�2. Simple Take-Home Test Helps Spot Early Alzheimer’s (Ivanhoe Newswire) - Researchers at The Ohio State University Wexner Medical Center have confirmed that the Self-Administered Gerocognitive Examination (SAGE test), which takes less than 15 minutes to complete, is a reliable tool for evaluating cognitive abilities.
�3. Stents for Sinusitis CHICAGO, Ill. (Ivanhoe Newswire) - 31 million Americans suffer from chronic sinusitis. When medications fail, seeking relief can often lead to surgery. Now, there’s a new device that can help guarantee permanent results.
�4. Poison Could Kill HIV Cells (Ivanhoe Newswire) - An engineered toxin has been shown to actually kill HIV cells that remained after antiretroviral treatment.
�5. Diet Foods that Aren’t (2nd week) SEATTLE (Ivanhoe Newswire) - This is the year - the year you’ve vowed to finally shed that extra weight! But you might be making poor choices without even knowing it.
�6. 7 Health Apps You Need to Know About! SAN DIEGO, Cali. (Ivanhoe Newswire) - When it comes to your phone, do you suffer from “app overload?” While there may be some you can do without, we want you to know about seven apps that could benefit your health.
�7. DVT Device Breaks Up Dangerous Clots (2nd week) CHICAGO, Ill. (Ivanhoe Newswire) - Every year, two million people develop deep vein thrombosis - a large blood clot in the leg that can be fatal. In the past, blood thinners were the only option, but the medication doesn’t help dissolve the clot itself. Now, a new device is changing that and helping prevent complications.
�8. New Therapy - New Hope for Aggressive Breast Cancer SEATTLE, Wash. (Ivanhoe Newswire) - Triple negative breast cancer accounts for about 15 percent of all new breast cancer cases in the U.S., but it leads to 25 percent of all breast cancer deaths. A diagnosis of triple negative breast cancer means that the three most common types of receptors known to fuel most breast cancer growth are not present in the cancer tumor. It’s an aggressive cancer that - until now - has only been treated with standard chemo. Now, a new therapy is offering patients hope for the first time.
�10. New Hope for Osteoporosis? (2nd week) (Ivanhoe Newswire) - In a phase 1 study, single injections of romosozumab (a humanized monoclonal anti-sclerostin antibody, stimulated bone formation, decreased bone resorption, and increased bone mineral density. Now, researchers have evaluated the efficacy and safety of romosozumab in postmenopausal women with low bone mass.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||